Prandin (repaglinide)
September 29, 2003
Audience: Endocrinologists, pharmacists and other healthcare providers
Novo Nordisk and FDA revised the PRECAUTIONS/Drug Interaction section of the prescribing information to inform healthcare professionals of a drug-drug interaction between repaglinide (PRANDIN), a short-acting insulin secretagogue, and gemfibrozil (Lopid) a lipid-lowering agent used to treat dyslipidemia.A study that evaluated the co-administration of gemfibrozil with PRANDIN in healthy subjects found a significant increase in repaglinide blood levels. Concomitant use may result in enhanced and prolonged blood glucose-lowering effects of repaglinide. For patients already on PRANDIN and gemfibrozil, blood glucose levels should be monitored and PRANDIN dose adjustment may be needed.
[Sept, 2003 Letter - Novo Nordisk] PDF Format
[August, 2003 Revised, highlighted label - Novo Nordisk] PDF Format
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.